Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mavacamten

- PMLiVE

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

Checkpoint inhibitor plus chemo meets first primary endpoint in late-stage trial

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress

- PMLiVE

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

Agreement will focus on development in oncology and haematology

- PMLiVE

BMS pledges $300m to tackle health inequity and improve diversity

Drugmaker announces a series of commitments to expand inclusion

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

- PMLiVE

BMS/bluebird bio resubmit FDA application for myeloma CAR-T

Novel CAR-T therapy targets heavily pre-treated myeloma

- PMLiVE

BMS suspends new clinical trials as COVID-19 cases rise in US

Existing sites can continue to recruit new subjects

- PMLiVE

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

Combination regimen didn't improve progression-free survival

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

BMS partners with Voluntis to co-develop oncology digital therapeutics

Aims to create a mobile app to help patients self-manage their symptoms

- PMLiVE

Lilly’s Trulicity scores CV reduction indication in the US

Approved for risk reduction in primary and secondary populations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links